ClinicalTrials.gg

Program

zosurabalpin

Its studies are mostly in Bacterial Infections, led by Hoffmann-La Roche.

Furthest: phase 1, since Oct 23, 20202 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche20 open or runningphase 1since Oct 23, 2020Oct 23, 2020none ahead
  • Named in Hoffmann-La Roche’s own pipeline as RG6006 zosurabalpin, phase 1, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 23, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04605718 · 124 enrolled · United States
  2. Nov 10, 2022Phase 1 study in Bacterial InfectionsNCT05614895 · 48 enrolled · United States, France, Israel and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05614895Bacterial Infections · United States, France, Israel and more1CompletedJan 13, 202448
NCT04605718Healthy Volunteers · United States1CompletedMar 9, 2023124

How it is read

Names in the registry

  • “RO7223280”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.